Leiden University Scholarly Publications

Your Search

Enabled Filters

  • (-) = Huisman, M.V.
  • (-) = Pollack, C.V.

Search results

  • RSS Feed
(1 - 7 of 7)
Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding
Wall, S.J. van der; Lopes, R.D.; Aisenberg, J.; Reilly, P.; Ryn, J. van; Glund, S.; ... ; Huisman, M.V. 2019
Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding
Article / Letter to editor
metadata only
Idarucizumab for Dabigatran Reversal - Full Cohort Analysis
Pollack, C.V.; Reilly, P.A.; Ryn, J. van; Eikelboom, J.W.; Glund, S.; Bernstein, R.A.; ... ; Weitz, J.I. 2017
Idarucizumab for Dabigatran Reversal - Full Cohort Analysis
Article / Letter to editor
metadata only
Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD (TM) study
Pollack, C.V.; Bernstein, R.; Dubiel, R.; Reilly, P.; Gruenenfelder, F.; Huisman, M.V.; ... ; Weitz, J.I. 2017
Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD (TM) study
Article / Letter to editor
metadata only
Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation
Grottke, O.; Aisenberg, J.; Bernstein, R.; Goldstein, P.; Huisman, M.V.; Jamieson, D.G.; ... ; Eikelboom, J. 2016
Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation
Article / Letter to editor
metadata only
Letter to the Editor: Managing Dabigatran-Related Bleeding
Levy, J.H.; Weitz, J.I.; Bernstein, R.A.; Eikelboom, J.; Hylek, E.; Huisman, M.V.; ... ; Pollack, C.V. 2016
Letter to the Editor: Managing Dabigatran-Related Bleeding
Article / Letter to editor
metadata only
Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran
Pollack, C.V.; Reilly, P.A.; Bernstein, R.; Dubiel, R.; Eikelboom, J.; Glund, S.; ... ; Weitz, J.I. 2015
Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran
Article / Letter to editor
metadata only
Dabigatran-related coagulopathy: when can we assume the effect has "worn off"?
Pollack, C.V.; Levy, J.H.; Eikelboom, J.; Weitz, J.I.; Sellke, F.W.; Huisman, M.V.; ... ; Bernstein, R.A. 2014
Dabigatran-related coagulopathy: when can we assume the effect has "worn off"?
Article / Letter to editor
metadata only